Klebsiella Pneumoniae Infection Drug Market

Klebsiella Pneumoniae Infection Drug Market contains market size and forecasts of Klebsiella Pneumoniae Infection Drug in global, including the following market information:
Global Klebsiella Pneumoniae Infection Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Klebsiella Pneumoniae Infection Drug Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Klebsiella Pneumoniae Infection Drug companies in 2021 (%)
The global Klebsiella Pneumoniae Infection Drug market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
ATI-1503 Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Klebsiella Pneumoniae Infection Drug include Acies Bio doo, Appili Therapeutics, Debiopharm International SA, Evaxion Biotech ApS, F. Hoffmann-La Roche Ltd, FOB Synthesis Inc, ImmunoClin Corp, Innovation Pharmaceuticals Inc and Kyorin Pharmaceutical Co Ltd, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Klebsiella Pneumoniae Infection Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Klebsiella Pneumoniae Infection Drug Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Klebsiella Pneumoniae Infection Drug Market Segment Percentages, by Type, 2021 (%)
ATI-1503
CA-824
CC-1807
Cefiderocol
Debio-1454
EBX-004
Others
Global Klebsiella Pneumoniae Infection Drug Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Klebsiella Pneumoniae Infection Drug Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Others
Global Klebsiella Pneumoniae Infection Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Klebsiella Pneumoniae Infection Drug Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Klebsiella Pneumoniae Infection Drug revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Klebsiella Pneumoniae Infection Drug revenues share in global market, 2021 (%)
Key companies Klebsiella Pneumoniae Infection Drug sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Klebsiella Pneumoniae Infection Drug sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Acies Bio doo
Appili Therapeutics
Debiopharm International SA
Evaxion Biotech ApS
F. Hoffmann-La Roche Ltd
FOB Synthesis Inc
ImmunoClin Corp
Innovation Pharmaceuticals Inc
Kyorin Pharmaceutical Co Ltd
Melinta Therapeutics Inc
Nosopharm SAS
Peptilogics Inc
Pfizer Inc
Phico Therapeutics Ltd
Sarepta Therapeutics Inc
Shionogi & Co Ltd
Syntiron LLC
Tetraphase Pharmaceuticals Inc